Division of Medicaid & Children’s Health Operations

MAY 03 2013

Dorothy Frost Teeter, Director
MaryAnne Lindeblad, Medicaid Director
Health Care Authority
P.O. Box 45502
Olympia, Washington 98504-5502

RE: Washington State Plan Amendment (SPA) Transmittal Number 13-003

Dear Ms. Teeter and Ms. Lindeblad

The Centers for Medicare & Medicaid Services (CMS) Pharmacy Team recently approved State Plan Amendment (SPA) 13-003 effective January 1, 2013, reflecting changes in pharmacy coverage required by Section 175 of the Medicare Improvement for Patients and Providers Act of 2008 which amended Section 1860D-2(e)(2)(A) of the Social Security Act.

The state has or will receive an approval of this SPA from the CMS Pharmacy Team. The Seattle Regional Office is also providing an additional copy as we were the recipient of the original, signed amendment request, and we maintain the official Washington State Plan. Enclosed you will find a copy of the official CMS form 179, amended page(s), and copy of the approval letter from the Pharmacy Team for your records.

If you have any questions concerning the Seattle Regional Office role in the processing of this SPA, please contact me, or have your staff contact Maria Garza at (206) 615-2542 or via email at maria.garza@cms.hhs.gov.

Sincerely,

Carol J.C. Peverly
Associate Regional Administrator
Division of Medicaid and Children’s Health Operations

Enclosure
May 3, 2013

Dorothy Frost Teeter, Director
MaryAnne Lindeblad, Medicaid Director
State of Washington Health Care Authority
P.O. Box 45502
Olympia, WA 98504-5502

Dear Ms. Teeter and Ms. Lindeblad:

We have reviewed Washington's State Plan Amendment (SPA) 13-003, received in the Seattle Regional Office on March 12, 2013. This amendment proposes to exclude from coverage benzodiazepines for all conditions and barbiturates for the treatment of epilepsy, cancer and chronic mental health disorders for full benefit dual eligibles as Medicare Part D will provide this coverage.

Based on the information provided, we are pleased to inform you that consistent with the regulations at 42 CFR 430.20, SPA WA 13-003 is approved with an effective date of January 1, 2013. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into the Washington state plan will be forwarded by the Seattle Regional Office.

If you have any questions regarding this amendment, please contact Jessica Walker at (410) 786-2457.

Sincerely,

Larry Reed
Director
Division of Pharmacy

cc: Carol Peverly, ARA, Seattle Regional Office
    Maria I. Garza, Seattle Regional Office
**TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL**

**FOR: HEALTH CARE FINANCING ADMINISTRATION**

**TO: REGIONAL ADMINISTRATOR**

HEALTH CARE FINANCING ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES

**5. TYPE OF PLAN MATERIAL (Check One):**

- NEW STATE PLAN
- AMENDMENT TO BE CONSIDERED AS NEW PLAN
- AMENDMENT

COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMENDMENT (Separate Transmittal for each amendment)

**6. FEDERAL STATUTE/REGULATION CITATION:**

- a. FFY 2013 ($896,426)
- b. FFY 2014 ($896,426)

**7. FEDERAL BUDGET IMPACT:**

- a. FFY 2013 ($896,426) P&I
- b. FFY 2014 ($896,426) P&I

**8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:**

- Att. 3.1-A pgs 32a, 32b
- Att. 3.1-B pgs 32a, 32b

**9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable):**

- Att. 3.1-A pgs 32a, 32b
- Att. 3.1-B pgs 32a, 32b

**10. SUBJECT OF AMENDMENT:**

Pharmacy – Part D Benefit Change

**11. GOVERNOR’S REVIEW (Check One):**

- GOVERNOR’S OFFICE REPORTED NO COMMENT
- COMMENTS OF GOVERNOR’S OFFICE ENCLOSED
- NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

**12. SIGNATURE OF STATE AGENCY OFFICIAL:**

**13. TYPED NAME:**

MaryAnne Lindeblad

**14. TITLE:**

Medicaid Director

**15. DATE SUBMITTED:**

8-12-13

**16. RETURN TO:**

Ann Myers

Rules and Publications

Legal and Administrative Services

Health Care Authority

626 8th Ave SE M3: 45504

Olympia, WA 98504-5504

**17. DATE RECEIVED:**

MAR 12 2013

**18. DATE APPROVED:**

May 3, 2013

**19. EFFECTIVE DATE OF APPROVED MATERIAL:**

January 1, 2013

**20. SIGNATURE OF REGIONAL OFFICIAL:**

Carol J.C. Peverly

**21. TYPED NAME:**

Carol J.C. Peverly

**22. TITLE:**

Associate Regional Administrator

Division of Medicaid & Children’s Health

**23. REMARKS:**

4.30.13 The state authorizes a P&I change to box 7 to put parentheses around both figures to indicate savings.
STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State ______________ WASHINGTON ______________

AMOUNT, DURATION AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

12. a. Prescribed Drugs (continued)

Citation

Provision

1935(d)(1) In January 2006, the Medicaid agency ceased covering any Part D drug for full-benefit dual eligible individuals who are entitled to receive Medicare benefits under Part A or Part B.

1927(d)(2) and 1935(d)(2)

(a) The Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid recipients, including full benefit dual eligible beneficiaries under the Medicare Prescription Drug Benefit—Part D.

X The following excluded drugs are covered:

select (i) Agents when used for anorexia, weight loss, weight gain: progestin derivative appetite stimulant, androgenic agents

no (ii) Agents when used to promote fertility

no (iii) Agents when used for cosmetic purposes or hair growth

select (iv) Agents when used for the symptomatic relief of cough and colds: antitussives, expectorants, decongestants, nasal spray, and only the following generic, single ingredient formulations:
- Guafenesin 100mg/5ml liquid or syrup;
- Dextromethorphan 15mg/5ml liquid or syrup;
- Pseudoephedrine 30mg or 60mg tablets;
- Saline nasal spray 0.65%; and
- Generic combination product: dextromethorphan-guaifenesin 10-100mg/5ml syrup, including sugar-free formulations.

X (v) Prescription vitamins and mineral products, except prenatal vitamins and fluoride, for documented deficiency.

select (vi) Nonprescription (OTC) drugs when determined by the department to be the least costly therapeutic alternative for a medically accepted indication: analgesics/antipyretics, antacids, antibacterial topical preparations, antidiarrheals, antiemetic/antivertigo agents, antiflatulents, antihistamines, antitussives, decongestants, electrolyte replacements, emetics, expectorants, eye antihistamines, fluoroide preparations, hyperglycemics, inhalation agents, insulins,

Approval Date May 3, 2013
Effective Date 1/1/13
12. a. Prescribed Drugs (continued)

laxatives, lipotropics, nasal preparations, topical antifungals, topical steroidal anti-inflammatory, topical antiparasitics

The Agency provides coverage of over-the-counter (OTC) tobacco cessation covered outpatient drugs for pregnant women regardless of age as recommended in "Treating Tobacco Use and Dependence – 2008 Update: A Clinical Practice Guideline" published by the Public Health Service in May 2008 or any subsequent modification of such guideline, when the pregnant woman is participating in either an Agency-approved smoking cessation program or counseling provided by her prescribing practitioner.

Over-the-counter drugs to promote smoking cessation will be covered for non-pregnant clients who are eighteen years of age or older and participating in an Agency-approved smoking cessation program.

none (vii) covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee

X (viii) Barbiturates (Except for dual eligible individuals, effective January 1, 2013, when used in the treatment of epilepsy, cancer, or a chronic mental health disorder as Part D will cover those indications.)

X (ix) Benzodiazepines (Except for dual eligible individuals, effective January 1, 2013, as Part D will cover all indications.)

X (x) Agents when used to promote smoking cessation (drugs not eligible under Part D and are not covered for dual-eligible clients):

- FDA-approved prescription drugs to promote smoking cessation will be covered, consistent with FDA guidelines for non-pregnant clients who are eighteen years of age or older and participating in an Agency-approved smoking cessation program.
- The Agency provides coverage of prescription tobacco cessation covered outpatient drugs for pregnant women regardless of age as recommended in "Treating Tobacco Use and Dependence – 2008 Update: A Clinical Practice Guideline" published by the Public Health Service in May 2008 or any subsequent modification of such guideline, when the pregnant woman is participating in either an Agency-approved smoking cessation counseling program or counseling provided by her prescribing practitioner.

No excluded drugs are covered.
12. a. Prescribed Drugs (continued)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Provision</th>
</tr>
</thead>
<tbody>
<tr>
<td>1935(d)(1)</td>
<td>Effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible individuals who are entitled to receive Medicare benefits under Part A or Part B.</td>
</tr>
<tr>
<td>1927(d)(2) and 1935(d)(2)</td>
<td>(a) The Medicaid agency provides coverage for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid recipients, including full benefit dual eligible beneficiaries under the Medicare Prescription Drug Benefit—Part D.</td>
</tr>
</tbody>
</table>

X The following excluded drugs are covered:

select (i) Agents when used for anorexia, weight loss, weight gain: Progestin derivative appetite stimulant, androgenic agents

No (ii) Agents when used to promote fertility

No (iii) Agents when used for cosmetic purposes or hair growth

select (iv) Agents when used for the symptomatic relief of cough and colds: antitussives, expectorants, decongestants, nasal spray, and only the following generic, single ingredient formulations:
- Guaiifenesin 100mg/5ml liquid or syrup;
- Dextromethorphan 15mg/5ml liquid or syrup;
- Pseudoephedrine 30mg or 60 mg tablets;
- Saline nasal spray 0.65%; and
- Generic combination product: dextromethorphan-guaifenesin 10-100mg/5ml syrup, including sugar-free formulations.

X (v) Prescription vitamins and mineral products, except prenatal vitamins and fluoride for documented deficiency

select (vi) Nonprescription (OTC) drugs when determined by the department to be the least costly therapeutic alternative for a medically accepted indication: analgesics/antipyretics, antacids, antibacterial topical preparations, antidiarrheals, antiemetic/antivertigo agents, antiflatulents, antihistamines, antitussives, decongestants, electrolyte replacements, emetics, expectorants, eye antihistamines, fluoride preparations, hyperglycemics, inhalation agents, insulins,
12. a. Prescribed Drugs (continued)

- laxatives, lipotropics, nasal preparations, topical antifungals, topical steroidal anti-inflammatory, topical antiparasitics

The Agency provides coverage of over-the-counter (OTC) tobacco cessation covered outpatient drugs for pregnant women regardless of age as recommended in "Treating Tobacco Use and Dependence – 2008 Update: A Clinical Practice Guideline" published by the Public Health Service in May 2008 or any subsequent modification of such guideline, when the pregnant woman is participating in either an Agency-approved smoking cessation counseling program or counseling provided by her prescribing practitioner.

Over-the-counter drugs to promote smoking cessation will be covered for non-pregnant clients who are eighteen years of age or older and participating in an Agency-approved smoking cessation program.

- **None** (vii) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee

- **X** (viii) Barbiturates (Except for dual eligible individuals, effective January 1, 2013, when used in the treatment of epilepsy, cancer, or a chronic mental health disorder as Part D will cover those indications.)

- **X** (ix) Benzodiazepines: (Except for dual eligible individuals, effective January 1, 2013, as Part D will cover all indications.)

- **X** (x) Agents when used to promote smoking cessation (drugs not eligible under Part D and are not covered for dual eligible clients):
  
  - FDA-approved prescription drugs to promote smoking cessation will be covered, consistent with FDA guidelines, for non-pregnant clients who are eighteen years of age or older and participating in an Agency-approved smoking cessation program.

  - The Agency will provide coverage of prescription and over-the-counter (OTC) tobacco cessation covered outpatient drugs for pregnant women regardless of age as recommended in "Treating Tobacco Use and Dependence ~ 2008 Update: A Clinical Practice Guideline" published by the Public Health Service in May 2008 or any subsequent modification of such guideline, when the pregnant woman is participating in either an Agency-approved smoking cessation counseling program or counseling provided by her prescribing practitioner.

  — No excluded drugs are covered.